SignalCorporate
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
Moderna stock falls on cost outlook amid revenue uncertainty.
Context
What happened: Moderna ($MRNA) presented its 2026 Analyst Day, highlighting oncology as a long-term growth driver alongside efforts to improve profitability in its infectious disease vaccine business. Shares fell after the update.
Key numbers: 2026 revenue growth expected at 15-25%. 2027 cash costs about $4 billion, and $4-$4.5 billion annually from 2027 through 2030.
Why it matters: The decline was likely tied to limited visibility into 2027 and longer-term revenue growth, while the company outlined substantial spending through 2030. Moderna carries a Zacks Rank #3 (Hold).
Market: -0.0% today ($50.62), +3.8% YTD, 0.1x vol — as of 16:03 UTC
What changed
Moderna ($MRNA) presented its 2026 Analyst Day, highlighting oncology as a long-term growth driver alongside efforts to improve profitability in its infectious disease vaccine business. Shares fell after the update.
Why it matters
The decline was likely tied to limited visibility into 2027 and longer-term revenue growth, while the company outlined substantial spending through 2030. Moderna carries a Zacks Rank #3 (Hold).
Market: -0.0% today ($50.62), +3.8% YTD, 0.1x vol — as of 16:03 UTC